Showing 4361-4370 of 10058 results for "".
- Study Links Vitiligo to Higher Autoimmune and Infection Burden in US Cohorthttps://practicaldermatology.com/news/vitiligo-linked-to-higher-autoimmune-and-infection-burden-in-us-cohort/2486572/New data from a large retrospective study suggested patients with vitiligo experience higher rates of several comorbidities and safety events compared with matched controls. Investigators analyzed Optum Market Clarity EHR dat
- Study: No Meaningful Link Between AD and Adolescent Academic Performancehttps://practicaldermatology.com/news/study-no-meaningful-link-between-ad-and-adolescent-academic-performance/2486567/Atopic dermatitis (AD) was not found to impair academic performance in adolscent patients, according to results from a new analysis of two large European cohorts. Researchers looked at two large, population-based cohort studi
- Paper: AI Gains Ground in Cosmetic Dermatology Workflowshttps://practicaldermatology.com/news/paper-ai-gains-ground-in-cosmetic-dermatology-workflows/2486551/A recent review in Dermatology and Therapy assessed the growing use of artificial intelligence (AI) across aesthetic dermatology, with the authors reporting increased adoption and highlighting its use in many aspects of prac
- Early Inflammatory Signals May Precede Alopecia Areata Diagnosishttps://practicaldermatology.com/news/early-inflammatory-signals-may-precede-alopecia-areata-diagnosis/2486446/Data from a new systematic review presented at the 2026 American Academy of Dermatology Annual Meeting indicated a consistently elevated neutrophil-to-lymphocyte ratio (NLR) in alopecia areata (AA).Investigators used data from PubMed, Embase, and Cochrane
- Tapinarof Shows Rapid Itch and Skin Improvement in Atopic Dermatitishttps://practicaldermatology.com/news/tapinarof-shows-rapid-itch-and-skin-improvement-in-atopic-dermatitis/2486493/New pooled Phase 3 data presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting highlight the rapid onset and consistent efficacy of tapinarof cream 1% (VTAMA; Organon) in patients with moderate-to-severe atopic dermatitis (AD), including children as young as 2 years. Th
- Lebrikizumab Shows Durable Efficacy Through 4 Years in Atopic Dermatitishttps://practicaldermatology.com/news/lebrikizumab-shows-durable-efficacy-through-4-years-in-atopic-dermatitis/2486468/Long-term data from the Phase 3b ADlong study show that lebrikizumab provides sustained skin clearance and itch relief for up to four years in patients with moderate-to-severe atopic dermatitis (AD), according to findings presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting.
- Molecular Profiling Reveals Personalized Pathways in Skin Aginghttps://practicaldermatology.com/news/molecular-profiling-reveals-personalized-pathways-in-skin-aging/2486451/A translational biomarker study presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting highlighted distinct molecular signatu
- Transcriptomic Study Identifies IL-1β Axis in Hidradenitis Suppurativahttps://practicaldermatology.com/news/transcriptomic-study-identifies-il-1b-axis-in-hidradenitis-suppurativa/2486448/Comprehensive transcriptomic profiling of hidradenitis suppurativa (HS) highlights a dominant macrophage-derived IL-1β/NLRP3 inflammasome axis, p
- TRuE-AD4: Ruxolitinib Cream Improves QoL and Sleep in Moderate ADhttps://practicaldermatology.com/news/true-ad4-ruxolitinib-cream-improves-qol-and-sleep-in-moderate-ad/2486434/Ruxolitinib cream 1.5% demonstrated consistent improvements in patient-reported outcomes among adults with moderate atopic dermatitis (AD) who previously had inadequate response, intolerance, or contraindications to topical corticosteroids (TCS) and topical calcine
- AAD Updates Systemic Therapy Guidelines for Adult ADhttps://practicaldermatology.com/news/aad-updates-systemic-therapy-guidelines-for-adult-atopic-dermatitis/2486418/The American Academy of Dermatology (AAD) has issued an interim update to its clinical practice guidelines for systemic treatment of moderate to severe atopic dermatitis (AD) in adults, reflecting the rapid expansion of evidence supporting targeted therapies. The u